Valuation
- Market cap
- —
- Revenue TTM
- $2,240,000
- Net income TTM
- $-42,190,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 3,100
- Avg volume
- 14,092
- Day's range
- $0.05 – $0.06
- Shares out
- —
- Stochastic %K
- 82%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- —
Company profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical...
Show more
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
- Phone
- 305 845 2813
- Website
- https://www.sab.bio
- Address
- 777 W 41st St., Miami Beach, United States
Latest news
No headlines yet.
